The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Zoryve foam, 0.3% is a once-daily topical treatment for plaque psoriasis on the body and scalp. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) topical foam ...

Scalp psoriasis often presents with ... reduction in the Scalp Itch Numeric Rating Scale at week eight compared to 30.3% in the placebo group. Treatment-emergent adverse events occurred more ...

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis ... from baseline in Scalp Itch-Numeric Rating Scale (SI-NRS).

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. Nearly 9 million ... by a ≥ 4-point change from baseline in Scalp Itch-Numeric Rating ...

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment ... Scalp-Investigator Global Assessment (S-IGA) and Body-IGA (B-IGA) scores. Both are five-point scales ...